NASDAQ:IMGN - ImmunoGen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.98 +0.15 (+2.57 %)
(As of 11/16/2018 04:00 PM ET)
Previous Close$5.98
Today's Range$5.67 - $6.03
52-Week Range$5.24 - $13.41
Volume2.08 million shs
Average Volume3.08 million shs
Market Capitalization$825.96 million
P/E Ratio-7.97
Dividend YieldN/A
Beta2.49
ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IMGN
Previous Symbol
CUSIP45253H10
Phone781-895-0600

Debt

Debt-to-Equity Ratio0.04
Current Ratio4.59
Quick Ratio4.56

Price-To-Earnings

Trailing P/E Ratio-7.97
Forward P/E Ratio-4.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$115.45 million
Price / Sales7.72
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book19.29

Profitability

EPS (Most Recent Fiscal Year)($0.75)
Net Income$-96,010,000.00
Net Margins-176.35%
Return on Equity-673.66%
Return on Assets-43.07%

Miscellaneous

Employees293
Outstanding Shares149,090,000
Market Cap$825.96 million
OptionableOptionable

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its earnings results on Friday, November, 2nd. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.01. The biotechnology company earned $10.90 million during the quarter, compared to analyst estimates of $13.60 million. ImmunoGen had a negative return on equity of 673.66% and a negative net margin of 176.35%. The company's quarterly revenue was up 28.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.61) EPS. View ImmunoGen's Earnings History.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release their next quarterly earnings announcement on Friday, February 8th 2019. View Earnings Estimates for ImmunoGen.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2018 earnings guidance on Friday, November, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50-55 million, compared to the consensus revenue estimate of $57.35 million.

What price target have analysts set for IMGN?

9 brokerages have issued 1 year target prices for ImmunoGen's shares. Their predictions range from $5.00 to $20.00. On average, they expect ImmunoGen's share price to reach $14.75 in the next year. This suggests a possible upside of 146.7% from the stock's current price. View Analyst Price Targets for ImmunoGen.

What is the consensus analysts' recommendation for ImmunoGen?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ImmunoGen.

What are Wall Street analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:
  • 1. HC Wainwright analysts commented, "The augmented balance sheet takes ImmunoGen into its potential marketing approval in 2020, in our view. ImmunoGen announced the closing of its previously disclosed underwritten public offering that netted approximately $163M on ImmunoGen’s balance sheet. As a result, ImmunoGen has ended 2Q18 with roughly $345.1M in cash and equivalents, and its bolstered balance sheet takes ImmunoGen one-plus years past the Phase 3 readout from the fully- enrolled FORWARD I program expected during 1H19, based on our calculations." (10/22/2018)
  • 2. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead ovarian cancer candidate, mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. The company’s shares have outperformed the industry so far this year." (9/24/2018)

Has ImmunoGen been receiving favorable news coverage?

Media headlines about IMGN stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ImmunoGen earned a news impact score of 0.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of ImmunoGen's key competitors?

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the folowing people:
  • Mr. Mark J. Enyedy, Pres, CEO & Director (Age 54)
  • Mr. David B. Johnston, Exec. VP & CFO (Age 63)
  • Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 60)
  • Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 63)
  • Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 48)

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.70%), FMR LLC (5.03%), Capital Research Global Investors (4.76%), Renaissance Technologies LLC (4.23%), Primecap Management Co. CA (2.54%) and Teachers Advisors LLC (1.64%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Which institutional investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, FMR LLC, Macquarie Group Ltd., Chicago Equity Partners LLC, Allianz Asset Management GmbH, Wells Fargo & Company MN, Renaissance Technologies LLC and Pinnacle Associates Ltd.. Company insiders that have sold ImmunoGen company stock in the last year include Anna Berkenblit, Daniel M Junius, David Brannon Johnston, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

Which institutional investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Man Group plc, Candriam Luxembourg S.C.A., Fosun International Ltd, Tekla Capital Management LLC, Teachers Advisors LLC, Capital Fund Management S.A. and Alps Advisors Inc.. View Insider Buying and Selling for ImmunoGen.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $5.98.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $825.96 million and generates $115.45 million in revenue each year. The biotechnology company earns $-96,010,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. ImmunoGen employs 293 workers across the globe.

What is ImmunoGen's official website?

The official website for ImmunoGen is http://www.immunogen.com.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]


MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  347 (Vote Outperform)
Underperform Votes:  361 (Vote Underperform)
Total Votes:  708
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2018 by MarketBeat.com Staff

Featured Article: Cost of Equity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel